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ABSTRACT 
MiR-150, a Novel and Potent Regulator for MLL-AF9 Leukemic Stem Cells. (May 2013) 
 
Patali Shikhi Cheruku 
Department of Biology 
Texas A&M University 
 
 
 
Research Advisor: Dr. Beiyan Zhou 
Department of Veterinary Physiology and Pharmacology 
 
 
 
MicroRNAs (miRNAs) are a class of short, non-coding RNAs that post-transcriptionally regulate 
gene expression, particularly in cancers. MicroRNA-150 has been proven as a critical regulatory 
for normal hematopoiesis and a potent inhibitor of MLL-AF9 leukemias. To understand the 
potential mechanism of how miR-150 suppresses MLL-AF9 leukemia through the regulation of 
leukemic stem cells (LSCs), the gain- and loss-of miR-150 strategies were adopted on an 
established MLL-AF9 expressing cell line. Gain-of-function will be carried out with miR-150 
overexpressing construct and loss-of-function of miR-150 will be performed by utilizing a newly 
established sponge system to achieve chromosomal recombination. The effect of miR-150 on 
MLL-AF9 LSCs will evaluated using multiple methodologies.  
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CHAPTER I 
INTRODUCTION 
 
The mixed lineage leukemia (MLL) gene codes for a histone methyltransferase that is crucial for 
early hematopoiesis. Chromosomal translocation can disrupt these genes to form fusion genes, 
which can lead to acute myeloid and lymphoid leukemias (AML and ALL). More than 70% of 
infantile and 10% of adult or treatment related leukemias are related to MLL mutations. One 
fusion oncogene, MLL-AF9, accounts for 80% of MLL-related infantile leukemias that exhibit 
mainly AML phenotypes1. Given that these leukemias are very aggressive and often have a high 
mortality rate, it is of great importance to understand their formation, regulatory mechanisms and 
other properties in order to develop effective treatments. 
 
One major breakthrough in this field of study is the identification of a leukemic-initiated cell 
population, termed leukemic stem cells (LSC). These cells can be derived from either 
hematopoietic stem cells or progenitor cells (HSC/PCs) with the recruitment of MLL-fusion 
genes and wild type MLL proteins2-4. Genome wide expression profiles comparing normal 
HSC/PCs and LSCs revealed that signaling pathways that are important for HSC/PCs survival 
are also shared by LSCs5-10. Characterization and mechanistic studies of LSCs is critical as these 
cells are responsible for the initiation and potential relapse of leukemias, however the overall 
framework, including epigenetic regulation, is not yet clear. 
 
MicroRNAs (miRNA) are a class of abundant, short (20-24 nucleotides), non-coding RNAs that 
have a regulatory purpose. They function by base pairing to sites within their target mRNAs and 
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prompt mRNA degradation or translational repression. Each miRNA targets multiple mRNAs 
and almost half of the mRNAs in mammalian cells are targeted by one or more miRNAs11-21. 
Many miRNAs regulate hematopoiesis22-32 and when abnormally expressed, some function as 
oncogenes24,29,33-36 and others as tumor suppressors34,36-38. However, the mechanisms and 
functions of miRNAs in hematopoiesis remain largely unknown. 
 
One miRNA in particular, microRNA-150 (miR-150), has been shown to have an influential 
regulatory role in hematopoiesis, specifically HSC function and progeny formation31,39. When 
prematurely expressed in HSC/PCs, miR-150 causes specific and severe defects in B cell 
production from the pre-B cell stage and beyond31. The tightly regulated miR-150 expression is 
crucial for normal hematopoietic differentiation, specifically for HSC/PCs and lineage 
differentiation. MiR-150 has also been shown to suppress MLL-AF9 leukemia. MLL fusion gene 
formation is associated with loss of MLL gene function and a global down regulation of 
miRNAs, one of the most down-regulated being miR-150, compared to other non-MLL leukemia 
cancers or other hematopoietic progenitors. When miR-150 expression was restored to a 
physiologically relevant level in MLL-AF9 expression cells, the cells’ survival, blast forming 
ability and LSC colony formation was significantly inhibited.  
 
The impact of a loss of miR-150, however, has not yet been studied.  Use of sponges has been 
proven as an effective method of inhibiting miRNAs.  These function by base-pairing with the 
miRNA so that the miRNA is no longer free to bind its target mRNA, and thereby produce the 
loss-of-function phenotype40.  A miR-150 sponge was constructed and tested in comparison with  
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an overexpression vector to determine the inhibitory effects of miR-150 on LSCs induced by the 
MLL-AF9 fusion protein. 
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CHAPTER II 
METHODS 
 
Cell culture conditions 
All cells were cultured in an incubator to maintain 37ºC with 5% CO2.  293T cells were cultured 
in Dulbecco’s Modified Eagle’s Medium with 10% fetal bovine serum (FBS); THP-1 cells 
(human acute monocytic cell line containing the MLL-AF9 oncogene) were obtained from 
ATCC and maintained in RPMI-1640 with 10% FBS.   
 
Table 1. DNA Oligonucleotide Sequences 
Oligos  
Synthesized by Integrated 
DNA Technologies 
Sequence 
miR-150 sponge forward 5’TCGAGTATTACACTGGTACAAGGGTTGGGAGAATTAC
ACTGGTACAAGGGTTGGGAGAATTACACTGGTACAAGG
GTTGGGAGAATTACACTGGTACAAGGGTTGGGAGAATC
GCGGGCC 3’ 
miR-150 sponge reverse 5’CGCGATTCTCCCAACCCTTGTACCAGTGTAATTCTCCC
AACCCTTGTACCAGTGTAATTCTCCCAACCCTTGTACCA
GTGTAATTCTCCCAACCCTTGTACCAGTGTAATAC 3’ 
BamHI forward 5’CTCGGATCCACCGGTCGC3’ 
SalI reverse 5’ATGTCGACCAGCTGGTCTTTCCGCCT3’ 
HoxA7 forward 5’CGGCCGAAGCCAGTTTC3’ 
HoxA7 reverse 5’GCGCCGCGTCAGGTAG3’ 
HoxA9 forward 5’GAATGAGAGCGGCGGAGAC3’ 
HoxA9 reverse 5’GAGCGAGCATGTAGCCAGTTG3’ 
Meis1 forward 5’GCAGTTGGCACAAGATACAGGAC3’ 
Meis1 reverse 5’ACTGCTCGGTTGGACTGGTCTA3’ 
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Plasmids and vectors 
The pcDNA5-CMV-d2eGFP-CXCR4 plasmid contains enhanced green florescence protein 
(eGFP) coding region and ampicillin resistance gene.  The pBabe-puro plasmid contains 
retroviral backbone and puromycin selection marker. GFP gene with 3’ untranslated fragments 
containing microRNA binding sites was inserted at the cloning sites after digestion with BamHI 
and SalI at 37ºC overnight.   
 
Construction of the miR-150 sponge retroviral construct 
The miR-150 sponge fragment consists of four repeated binding elements complimentary to 
miR-150 along with one XhoI and one ApaI overhang nucleotide sequences.  These oligos 
(Table 1) were annealed by incubating at 100ºC for five minutes, and then cooled to room 
temperature for one hour.  The pcDNA5-CMV-d2eGFP-CXCR440 plasmid was digested with 
XhoI and ApaI at 25ºC for 2 hours then 37ºC overnight and the large fragment (pCDNA5-CVM-
d2eGFP) was gel purified.  The annealed sponge fragment was then ligated into the digested 
vector at 14ºC overnight. The ligation mixture was transformed into DH5α competent cells (Z-
Competent™ E. coli from Zymo Research) and plated on Luria-Bertani (LB) agar plates 
containing 50 ug/mL ampicillin.  A colony was selected and cultured overnight in 5ml LB broth 
with 100ug/mL ampicillin.  The plasmid was extracted using the Qiaprep Spin Miniprep kit 
according to the manufacturer’s protocol. Enzymatic digestion with XhoI and ApaI confirmed 
the insertion of the miR-150 sponge fragment.  The miR-150sp-eGFP sequence (Figure 1) was 
then amplified using polymerase chain reaction (PCR) with the BamHI forward and SalI reverse 
primers, gel purified, then digested with BamHI and SalI and ligated into the digested pBabe-
puro40 plasmid.  The product was prepared using the procedure previously described.  The 
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presence of the miR-150sp-eGFP sequence was confirmed using restriction digest analysis and 
sequencing.  The function of the miR-150 sponge was determined by luciferase reporter analysis. 
FIGURE 1.  MicroRNA sponge gene 
The microRNA sponge gene containing the miR-150 binding sites was cloned into the 3’UTR of 
2-h destabilized enhanced GFP reporter gene. 
 
Retroviral infection 
Mir-150 overexpression was generated using a pLB1-miR150 lentiviral vector.  This plasmid 
was transfected into 293T cells and miR-150 overexpression of the gene was determined by GFP 
expression and quantitative RT-PCR (qRT-PCR).  To generate lentiviral supernatant, the 293T 
cells were pre-plated at 30% confluency one day before transfection of pLB1-miR150, a VSV-G 
expression vector (pHCVM-G) and a gag/pol expression vector (pCVMΔR8.9) with 
Lipofectamine 2000.  The supernatant was collected after 48 and 72 hours and used for infection.  
The THP-1 cells were suspended in the viral supernatant and centrifuged at 720 x g for 90 
minutes before culturing.  The pBabe-miR150sp vector was transfected into the THP-1 cells 
using a similar procedure. 
 
RT-qPCR 
Total RNA was extracted at specific time points from treated THP-1 cells using the Trizol 
extraction protocol according to the manufacturer’s instructions.  Gene expression analysis was 
performed by quantitative RT-PCR with iScript One-Step RT-PCR kit with SYBR Green (Bio-
Rad) using the primer pairs specified in Table 1.  The data presented correspond to the mean of 
Pol II 
promotor 
d2eGFP AAAAAA..  
miRNA target sequences 
(bulged or perfect match) 
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2-ΔΔCt from at least three independent experimental repeats and normalized to β-Actin or 
GAPDH reference genes.  
 
Flow cytometry 
The effects of miR-150 on THP-1 cells were evaluated by analyzing cell growth, apoptosis, cell 
cycle, and stem cell populations.  The leukemic stem cell population is defined as Lin-(depleted 
with antibodies against CD4 and CD8 T cells, B220 for B cells, CD11b and CD11c for Myeloid 
cells) c-Kit+, Sca-1- cells. Fluorescence conjugated antibodies are obtained from eBioscience 
and flow cytometry analysis was performed using BD Accuri 6. Data were analyzed using 
FlowJo 7.6. 
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CHAPTER III 
RESULTS 
 
Designing miR-150 sponge primer set 
 To ensure the binding of miR-150 to the target sponge construct, DNA primers of 120 
nucleotide (nt) and 112nt in length, forward and reverse primers respectively, were designed 
which harbor four miR-150 perfectly complementary binding motifs, each of them 22nt in length 
connected by a 4nt spacer (Figure 2).  
Preparation of the DNA fragment containing the miR-150 sponge sequence 
The forward and reverse miR-150 sponge primers were annealed in order to obtain a double-
stranded DNA fragment of the sponge with overhanging ends to match Xho1 and ApaI digestion.  
Two micrograms of both the forward and reverse primers were added to make a 50 uL reaction 
mixture in annealing buffer (100mM potassium acetate, 300mM HEPES-KOH, pH 7.4, 2mM 
magnesium acetate). The primers were heated to 100ºC for 5 minutes, and then allowed to 
gradually cool at room temperature for 1 hour.  The annealing product will be used for ligation. 
 
Construction of pcDNA5-CMV-d2eGFP-miR150sp 
To prepare the vector construct, the CXCR4 shRNA fragment was first released from pcDNA5-
CMV-d2eGFP-CXCR4 (Figure 3).  The digested vector was gel purified using the QIAquick Gel 
Extraction Kit (Qiagen).  After purification, the concentration was measured using the 
NanoDrop-1000® spectrophotometer (Thermo Scientific) and adjusted to 80 ng/uL.  
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FIGURE 2. miR-150 sponge DNA primer set 
2A. Forward and reverse sequences of the miR-150 sponge.  Xho1 and Apa1 overhang regions 
are indicated in green, spacer nucleotides in yellow, and miR-150 binding sites in blue. 
 
Forward: 
5’TCGAGTATTACACTGGTACAAGGGTTGGGAGAATTACACTGGTACAAGGGTTGGG
AGAATTACACTGGTACAAGGGTTGGGAGAATTACACTGGTACAAGGGTTGGGAGAA
TCGCGGGCC 3’ 
 
Reverse: 
5’CGCGATTCTCCCAACCCTTGTACCAGTGTAATTCTCCCAACCCTTGTACCAGTGTA
ATTCTCCCAACCCTTGTACCAGTGTAATTCTCCCAACCCTTGTACCAGTGtTAATAC 3’ 
 
2B.  Diagram of pcDNA5-CMV-d2eGFP-miR150sp 
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FIGURE 3.  pcDNA5-CMV-d2eGFP-CXCR4 after digestion with XhoI and ApaI 
After enzymatic digestion, the empty pcDNA5-CMV-d2eGFP (CMV) and CXCR4 fragments 
were visualized on a 1.2% agarose gel with a 1kb DNA ladder. 
 
 
 
The annealed product from the previous step was ligated into the purified vector using T4 DNA 
ligase (Invitrogen) following the manufacturer’s protocol.  The ligation product was then 
transformed into E. coli competent cells using a version of the manufacturer’s protocol: the 
ligation product was incubated on ice with 45 uL of cells for 15 minutes, 200 uL SOC was 
added, and the cells were plated on LB agar containing ampicillin.  After 10-16 hours of culture 
on agar plates containing ampicillin, bacteria containing the successful insertion of the fragment 
were observed by colony formation.  Single colonies were selected and amplified in LB broth 
    Marker      undigested            double digested 
  CMV   CMV 
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containing ampicillin for 10-16 hours. The plasmid was extracted and the insertion was 
confirmed by enzymatic digestion with XhoI and ApaI (Figure 4).  
FIGURE 4.  Confirmation of miR-150 sponge insertion 
After enzymatic digestion with XhoI and ApaI, the miR-150 sponge fragment (miR-150sp) and 
the digested empty pcDNA5-CMV-d2eGFP (CMV) were visualized on a 1.2% agarose gel with 
a 1kb DNA ladder. 
 
 
 
Construction of pBabe-d2eGFP-miR150sp 
To transfer the d2eGFP gene coding region with the miR-150sp fragment into a retroviral 
construct, two primers (Table 1: BamHI forward and SalI reverse) flanking the desired region 
were applied to amplify the target sequence. The PCR product at approximately 1000nt (Figure 
5) was gel purified, concentrated to 5 uL and digested with BamHI and SalI, followed by a 
Marker digested 
  CMV 
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second gel purification. The pBabe-puro vector was digested with BamHI and SalI (Figure 6) 
followed by gel purification.  
FIGURE 5.  Purification of PCR product 
After PCR amplification, d2eGFP-miR150sp (PCR product) was visualized and purified from a 
1.5% agarose gel with a 1kb DNA ladder. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1,000bp 
 
PCR product 
 
 
Marker   PCR product 
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FIGURE 6.  pBabe-puro after digestion with BamHI and SalI 
After enzymatic digestion the digested empty pBabe-puro vector was visualized and purified 
from a 1.2% agarose gel with a 1kb DNA ladder. 
 
  
 
Future steps 
Complete the construction of the miR-150 sponge system 
The PCR product will be inserted into the digested pBabe-puro (Figure 6) by ligation.  After 
transformation and plasmid extraction, the construct will be sequenced to confirm the presence 
of the d2eGFP-miR-150sp gene.  
    Marker        undigested   digested 
   pBabe   pBabe 
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Evaluation of miR-150 sponge using reporter assays  
The knockdown efficiency will be evaluated using luciferase assay to evaluate the efficiency of 
miR-150 inhibition on a reporter construct containing the luciferase gene-coding region followed 
by an untranslated region containing a miR-150 binding site.  Compared to samples without 
miR-150sp, we expect to see a recovery of luciferase activity as a result of the miR-150sp 
neutralization effect.   
 
Investigation miR-150 regulation on LSCs using constructed overexpression and miR-150 
sponge systems 
The retroviral supernatant will be generated using 293T cells and used to infect MLL-AF9 cells 
to evaluate the loss of miR-150 on LSC characteristics and survival.  Accordingly, gain of miR-
150 function on LSCs will be evaluated using similar procedures after transduction of miR-150 
overexpression construct, pLB1-miR150.  The frequency of LSCs will be determined by flow 
cytometry analysis using antibodies to identify Lin-, c-Kit+, Sca-1- cells.   Lower proliferation 
rates of LSCs are expected with ectopic miR-150 overexpression and higher rates are expected 
with the presence of the miR150 sponge.  
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CHAPTER IV 
DISCUSSION 
 
It has been shown that miR-150 expression is down regulated in several cancer types, including 
MLL-AF9 leukemia.  After overexpression, both in vivo and in vitro, miR-150 reduces survival 
and proliferation of leukemic cells. Whole gene transcriptome analysis revealed that restoration 
of miR-150 suppressed more than 30% of genes specifically expressed in stem cells 
(unpublished results).  In order to gain a better understanding of the mechanism through which 
this occurs, the loss-of-function phenotype should be studied, as well.  However, it is difficult to 
knock down microRNA levels effectively in vivo, we adopted a microRNA sponge design that 
allows investigation of miR-150 using a loss of function strategy.  
 
The rational of a microRNA sponge system utilizes complementary binding sites for a 
microRNA of interest, specifically miR-150 in this study. However, the efficiency of microRNA 
knockdown can be improved with several modification options. One option is to introduce a 
bulge in the binding sequence resulted from mismatch to the mature miR-150 sequence which 
has been shown to increase the stability of the microRNA sponge40.  If inefficient transfection or 
infection occurs, a lentiviral vector might be used instead of the retroviral pBabe plasmid. 
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